U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Approval Year

2022
358
Substance Class Protein
Created
by admin
on Sat Dec 16 14:04:42 GMT 2023
Edited
by admin
on Sat Dec 16 14:04:42 GMT 2023
Protein Type BISPECIFIC ANTIBODY
Protein Sub Type IGG1
Sequence Origin HUMANIZED MOUSE
Sequence Type COMPLETE
Record UNII
QC4F7FKK7I
Record Status Validated (UNII)
Record Version
  • Download
Related Record Type
Name Type Language
FARICIMAB
USAN   INN  
Official Name English
FARICIMAB [JAN]
Common Name English
RG-7716
Common Name English
RO6867461
Code English
IMMUNOGLOBULIN G1, ANTI-(HUMAN ANGIOPOIETIN 2) (HUMAN MONOCLONAL HEAVY CHAIN), DISULFIDE WITH HUMAN MONOCLONAL LIGHT CHAIN, DIMER WITH IMMUNOGLOBULIN G1, ANTI-(HUMAN VASCULAR ENDOTHELIAL GROWTH FACTOR A) (HUMAN-MUS MUSCULUS MONOCLONAL HEAVY CHAIN), DISUL
Systematic Name English
RO-6867461
Code English
FARICIMAB [USAN]
Common Name English
IMMUNOGLOBULIN G1-KAPPA/LAMBDA WITH DOMAIN CROSSOVER, ANTI-(HOMO SAPIENS-VASCULAR ENDOTHELIAL GROWTH FACTOR A (VEGF-A, VASCULAR PERMEABILITY FACTOR, VPF)) AND ANTI-(HOMO SAPIENS-ANGIOPOIETIN-2 (ANG-2)), HUMANIZED AND HOMO SAPIENS MONOCLONAL ANTIBODY, BIS
Systematic Name English
Faricimab [WHO-DD]
Common Name English
RG7716
Code English
faricimab [INN]
Common Name English
Y8HA1I28D3
Common Name English
RG-7716 (ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR/ANTI-ANGIOPOIETIN 2 BISPECIFIC ANTIBODY)
Common Name English
Code System Code Type Description
NCI_THESAURUS
C174885
Created by admin on Sat Dec 16 14:04:42 GMT 2023 , Edited by admin on Sat Dec 16 14:04:42 GMT 2023
PRIMARY
INN
10563
Created by admin on Sat Dec 16 14:04:42 GMT 2023 , Edited by admin on Sat Dec 16 14:04:42 GMT 2023
PRIMARY
WIKIPEDIA
Faricimab
Created by admin on Sat Dec 16 14:04:42 GMT 2023 , Edited by admin on Sat Dec 16 14:04:42 GMT 2023
PRIMARY
DAILYMED
QC4F7FKK7I
Created by admin on Sat Dec 16 14:04:42 GMT 2023 , Edited by admin on Sat Dec 16 14:04:42 GMT 2023
PRIMARY
DRUG BANK
DB15303
Created by admin on Sat Dec 16 14:04:42 GMT 2023 , Edited by admin on Sat Dec 16 14:04:42 GMT 2023
PRIMARY
EVMPD
SUB194079
Created by admin on Sat Dec 16 14:04:42 GMT 2023 , Edited by admin on Sat Dec 16 14:04:42 GMT 2023
PRIMARY
RXCUI
2591519
Created by admin on Sat Dec 16 14:04:42 GMT 2023 , Edited by admin on Sat Dec 16 14:04:42 GMT 2023
PRIMARY
USAN
FG-178
Created by admin on Sat Dec 16 14:04:42 GMT 2023 , Edited by admin on Sat Dec 16 14:04:42 GMT 2023
PRIMARY
CAS
1607793-29-2
Created by admin on Sat Dec 16 14:04:42 GMT 2023 , Edited by admin on Sat Dec 16 14:04:42 GMT 2023
PRIMARY
FDA UNII
QC4F7FKK7I
Created by admin on Sat Dec 16 14:04:42 GMT 2023 , Edited by admin on Sat Dec 16 14:04:42 GMT 2023
PRIMARY
CAS
2091719-64-9
Created by admin on Sat Dec 16 14:04:42 GMT 2023 , Edited by admin on Sat Dec 16 14:04:42 GMT 2023
NO STRUCTURE GIVEN
From To
1_22 1_96
1_156 1_216
1_236 3_213
1_242 2_232
1_245 2_235
1_277 1_337
1_383 1_441
2_22 2_96
2_150 2_206
2_226 4_214
2_267 2_327
2_373 2_431
3_22 3_87
3_137 3_193
4_23 4_88
4_134 4_194
Glycosylation Type MAMMALIAN
Glycosylation Link Type Site
N 1_313
N 2_303
Related Record Type Details
FARICIMAB-SVOA
SUB_CONCEPT->SUBSTANCE
HUMAN VASCULAR ENDOTHELIAL GROWTH FACTOR A
TARGET -> INHIBITOR
ANGIOPOIETIN-2
TARGET -> INHIBITOR
Related Record Type Details
FARICIMAB
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Molecular Formula CHEMICAL
MOL_WEIGHT:NUMBER(CALCULATED) CHEMICAL
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966